AQR Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

AQR Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.54M	Buy	675,014 +513,736	+319%	+$4.05M	﹤0.01%	2072
2026 Q1	$1.25M	Buy	161,278 +117,875	+272%	+$860K	﹤0.01%	2646
2025 Q4	$266K	Buy	+43,403	New	+$469K	﹤0.01%	3224
2025 Q3	–	Sell	-11,218	Closed	-$146K	–	3466
2025 Q2	$146K	Sell	11,218 -849	-7%	-$10K	﹤0.01%	3115
2025 Q1	$128K	Buy	+12,067	New	+$192K	﹤0.01%	2970
2024 Q4	–	Sell	-12,078	Closed	-$280K	–	2870
2024 Q3	$280K	Buy	12,078 +378	+3%	+$8.09K	﹤0.01%	2423
2024 Q2	$285K	Sell	11,700 -62,525	-84%	-$1.9M	﹤0.01%	2289
2024 Q1	$2.51M	Sell	74,225 -85,648	-54%	-$3.03M	﹤0.01%	1309
2023 Q4	$5.04M	Sell	159,873 -12,329	-7%	-$293K	0.01%	947
2023 Q3	$4.4M	Buy	172,202 +121,526	+240%	+$3.74M	0.01%	978
2023 Q2	$1.45M	Buy	+50,676	New	+$1.38M	﹤0.01%	1401
2021 Q1	–	Sell	-11,914	Closed	-$517K	–	2189
2020 Q4	$517K	Sell	11,914 -4,842	-29%	-$328K	﹤0.01%	1765
2020 Q3	$719K	Buy	+16,756	New	+$832K	﹤0.01%	1573

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

AQR Capital Management's ARCT Position: Q2 2026 in Review

AQR Capital Management increased its Arcturus Therapeutics (ARCT) stake by 319% in Q2 2026, buying an estimated $4.05M and bringing the position to 675,014 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

AQR Capital Management first reported a position in ARCT in Q3 2020 and has held it in 13 quarters since. The position peaked at $5.04M in Q4 2023. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

AQR Capital Management held 675,014 shares of Arcturus Therapeutics worth $4.54M as of Q2 2026.
AQR Capital Management bought 513,736 Arcturus Therapeutics shares in Q2 2026, an estimated $4.05M.
Arcturus Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2072 holding.
AQR Capital Management first reported a position in Arcturus Therapeutics in Q3 2020 and has held it in 13 quarters since.
AQR Capital Management's Arcturus Therapeutics position peaked at $5.04M in Q4 2023.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.